Table 2.
Clinical and pathologic characteristics of the patients according to TERT promoter mutation status.
| Variables | All (n = 622) |
Wild Type TERT
(n = 609) |
TERT Promoter Mutation (n = 13) | p-Value |
|---|---|---|---|---|
| Age (years, mean ± sd) | 47.190 ± 12.912 | 46.795 ± 12.616 | 65.692 ± 13.628 | <0.001 |
| <55 | 438 | 436 | 2 | <0.001 |
| ≥55 | 184 | 173 | 11 | |
| Sex | ||||
| Male | 132 | 131 | 1 | 0.319 |
| Female | 490 | 478 | 12 | |
| Bethesda category | ||||
| I | 4 | 4 | 0 | 0.869 |
| II | 23 | 22 | 1 | |
| III | 30 | 30 | 0 | |
| IV | 14 | 14 | 0 | |
| V | 123 | 121 | 2 | |
| VI | 428 | 418 | 10 | |
| Tumor location | ||||
| Right | 94 | 266 | 5 | 0.821 |
| Left | 13 | 239 | 5 | |
| Isthmus | 244 | 13 | 0 | |
| Bilateral | 271 | 91 | 3 | |
| Thyroidectomy | ||||
| Lobectomy, isthmectomy | 251 | 250 | 1 | 0.019 |
| Total, completion | 371 | 359 | 12 | |
| Lymph node dissection | ||||
| Less than central | 574 | 569 | 9 | 0.013 |
| Lateral node dissection | 48 | 44 | 4 | |
| Surgical approach | ||||
| Open | 260 | 252 | 8 | 0.163 |
| Endoscopic, robotic | 362 | 357 | 5 | |
| Operation time (minutes, mean ± sd) | 125.660 ± 49.471 | 125.218 ± 49.043 | 146.154 ± 65.770 | 0.276 |
| Blood loss (ml, mean ± sd) | 51.892 ± 73.573 | 51.900 ± 73.371 | 51.538 ± 85.814 | 0.988 |
| Histologic subtypes | ||||
| PTC (Classic type) | 583 | 574 | 9 | 0.006 |
| Variant | 39 | 35 | 4 | |
| Tumor size (cm, mean ± sd) | 1.033 ± 0.883 | 1.006 ± 0.829 | 2.285 ± 1.938 | 0.035 |
| ≤1 cm | 415 | 411 | 4 | 0.013 |
| >1 cm | 207 | 198 | 9 | |
| Multiplicity | ||||
| Single | 372 | 366 | 6 | 0.393 |
| Multiple | 250 | 243 | 7 | |
| Extrathyroidal extension | ||||
| Absent | 456 | 451 | 5 | 0.008 |
| Present | 166 | 158 | 8 | |
| Surgical margin | ||||
| Negative | 552 | 545 | 7 | 0.001 |
| Positive | 70 | 64 | 6 | |
| Lymphatic invasion | ||||
| Absent | 426 | 420 | 6 | 0.195 |
| Indeterminate | 68 | 66 | 2 | |
| Present | 128 | 123 | 5 | |
| Angioinvasion | ||||
| Absent | 547 | 538 | 9 | <0.001 |
| Indeterminate | 63 | 62 | 1 | |
| Present | 12 | 9 | 3 | |
| BRAFV600E mutation | ||||
| Negative | 108 | 106 | 2 | <0.001 |
| Positive | 514 | 503 | 11 | |
| T stage | ||||
| T1 | 499 | 495 | 4 | <0.001 |
| T2 | 26 | 26 | 0 | |
| T3 | 66 | 61 | 5 | |
| T4 | 31 | 27 | 4 | |
| N stage | ||||
| N0, Nx | 362 | 354 | 8 | 0.003 |
| N1a | 212 | 211 | 1 | |
| N1b | 48 | 44 | 4 | |
| Overall stage | ||||
| I | 544 | 540 | 4 | <0.001 |
| II | 62 | 57 | 5 | |
| III | 16 | 12 | 4 | |
| IV | 0 | 0 | 0 | |
| MACIS score | ||||
| <6 | 557 | 555 | 4 | <0.001 |
| 6–6.69 | 57 | 52 | 5 | |
| ≥7 | 6 | 2 | 4 | |
| Radioactive iodine therapy | ||||
| No | 394 | 391 | 3 | 0.006 |
| Yes | 228 | 218 | 10 |